Akeso’s ivonescimab meets next Phase III lung cancer goal, as competitors line up

Results from a Phase III study of ivonescimab in China address a key question for the competitive PD-1 x VEGF bispecific field: whether the drug’s striking monotherapy lung cancer results would extend to the more clinically relevant chemo combination setting. The answer appears to be yes, though with some nuances.

With that question at least partly resolved, the conversation is shifting from whether the leading PD-1 x VEGF bispecific’s efficacy signals are real to how durable, differentiated and competitive they will look as the increasingly crowded field generates more results...